GSK2798745
Unknown / undisclosed
Evidence outlook · program status
Discontinued (2022-04), after a negative readout
GSK2798745 is GSK's TRPV4 channel blocker, taken through heart failure, chronic cough and diabetic macular edema. Its last study, the diabetic macular oedema Phase 1, was terminated for futility on 2022-04-11; the chronic cough study NCT03372603 had already been terminated for lack of efficacy and no GSK2798745 study has started since. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04292912 NCT04292912 · Macular Edema This was a small, single-group, open-label study with no control group and no blinding, intended to characterize safety and drug behavior rather than prove a treatment effect, and it was stopped early after an interim review found it unlikely to meet its goals. Registry: NCT04292912 | 1 | Number of Participants With Abnormal Ophthalmic Examination Findings (Up to Day 28); Mean Change From Baseline to Day 28 in Visual Acuity (Baseline and Day 28); Mean Change From Baseline to Day 28 in Body Weight (Baseline and Day 28); Mean Change From Baseline to Day 28 in Body Temperature (Baseline and Day 28); Mean Change From Baseline to Day 28 in Vital Signs for Systolic Blood Pressure and Diastolic Blood Pressure (Baseline and Day 28); Mean Change From Baseline to Day 28 in Pulse Rate (Baseline and Day 28); Mean Change From Baseline to Day 28 in 12-lead Electrocardiogram (ECG) Findings (Baseline and Day 28); Mean Change From Baseline to Day 28 in Alanine Amino Transferase (ALT), Alkaline Phosphatase (AP), Aspartate Amino Transferase (AST), and Creatine Kinase (Baseline and Day 28); Mean Change From Baseline to Day 28 in Calcium, Glucose, Potassium, Sodium, and Urea Nitrogen (Baseline and Day 28); Mean Change From Baseline to Day 28 in Creatinine, Total Bilirubin, and Direct Bilirubin (Baseline and Day 28); Mean Change From Baseline to Day 28 in Clinical Chemistry Parameter Values of Protein (Baseline and Day 28); Mean Change From Baseline to Day 28 in Clinical Chemistry Parameter Values of Cardiac Troponin (Baseline and Day 28); Mean Change From Baseline to Day 28 in Basophils, Eosinophils, Leukocytes, Monocytes, Lymphocytes, Neutrophils, and Platelets (Baseline and Day 28); Mean Change From Baseline to Day 28 in Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb) (Baseline and Day 28); Mean Change From Baseline to Day 28 in Mean Corpuscular Hemoglobin (Baseline and Day 28); Mean Change From Baseline to Day 28 in Mean Corpuscular Volume (MCV) (Baseline and Day 28); Mean Change From Baseline to Day 28 in Erythrocytes (Baseline and Day 28); Mean Change From Baseline to Day 28 in Hematocrit (Baseline and Day 28); Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Ocular and Non-ocular AEs and SAEs (Until follow-up (Up to Day 56)); Mean Change From Baseline to Day 28 in Center Subfield Retinal Thickness as Measured by Spectral-Domain Optical Coherence Tomography (SD-OCT) (Baseline and Day 28) 2022-04-11 | Number of Participants With Abnormal Ophthalmic Examination Findings (Up to Day 28): GSK2798745 — Eyelids and Lashes: 0 Participants; Pupil motility: 0 Participants; Confrontation visual field examination: 0 Participants; Slit lamp evaluation of anterior ocular structures: 0 Participants; Intraocular pressure measurement, Left eye: 1 Participants; Intraocular pressure measurement, Right eye: 1 Participants; OCT center subfield, Left eye: 0 Participants; OCT center subfield, Right eye: 1 Participants | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.